46.58
+4.56%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Joinn Laboratories China Co
Its shares trade on Shanghai under the ticker 603127.SS. It has been listed since 25 August 2017. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.66bn and net income of CN¥297.8m. At that date it held total assets of CN¥9.68bn and shareholders' equity of CN¥8.32bn.
Joinn Laboratories China Co Ltd is a CN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Beijing, Beijing. The company went IPO on 2017-08-25. Joinn Laboratories China Co Ltd is a China-based company primarily engaged in the pharmacology and toxicology research of new drugs. Non-clinical research services include drug safety evaluation, pharmacokinetic research as well as pharmacological and pharmacodynamic research. Clinical trials and related services include clinical contract research organization services, phase I clinical research collaboration unit (CRU), and bioanalysis services. Experimental model business mainly includes rodents and non-human primates. The firm conducts its businesses both in the domestic market and overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 25 Aug 2017
- Employees
- 2,788
- Website
- joinnlabs.com ↗
Leadership
Pay as last reported
- Ms. Yuxia FengChairman of the Board, since 2012CN¥3.2m
- Ms. Aishui YuChief Financial OfficerCN¥1.3m
- Mr. Dapeng GaoGeneral Manager, Secretary of the Board, Director, since 2019CN¥1.9m
- Mr. Jingliang GuDeputy General Manager, Executive Director, since 2019CN¥1.9m
- Ms. Xi LuoDeputy General Manager, Executive Director, since 2023
- Ms. Yunxia SunDeputy General Manager, Director, since 2019CN¥1.9m
- Mr. Changyun YangIndependent Director
- Mr. Fuquan YangIndependent Director
- Mr. Fangtian YingIndependent Director
- Mr. Fan ZhangIndependent DirectorCN¥162,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 74
- Environment
- 73
- Social
- 64
- Governance
- 84
- Direct emissions (scope 1)
- 796.08 t
- Energy emissions (scope 2)
- 36,406.66 t
- Women in the workforce
- 65.9%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- 2,788 employees support comprehensive life sciences research services in China.
- Beijing headquarters enables strong domestic market presence and access to key resources.
- IPO in 2017 provides stable capital for expanding pharmacology and toxicology research.
Weaknesses
- Non-clinical research services face competition from established global firms in pharmacokinetic research.
- Experimental model business relies heavily on rodents and non-human primates, limiting diversification.
- Clinical trials services require significant capital investment for phase I CRU operations.
Opportunities
- Growing demand for new drug development in China's health care sector presents expansion potential.
- Overseas markets offer opportunities to leverage clinical contract research organization services internationally.
- Domestic market growth in pharmacological research supports continued service demand.
Threats
- Regulatory changes in China's health care industry could impact non-clinical research operations.
- Increased competition from international firms in toxicology research may reduce market share.
- Global economic downturns might affect funding for clinical trials and related services.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.